Transgenic Mouse Model for Multiple System Atrophy Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack an effective animal model to study multiple system atrophy (MSA), a rare neurodegenerative disease, and the role of bacterial infections in triggering synucleinopathy, which is crucial for understanding disease progression and developing therapeutic interventions.
Innovation Solution
A mouse model is developed by inactivating rodent alpha-synuclein and introducing a transgene expressing human alpha-synuclein, where injection of alpha-synuclein aggregates into the urinary bladder leads to oligodendroglial pathology and motor deficits, mimicking key features of MSA, and demonstrating that bacterial infections can trigger synucleinopathy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If transgenic mouse model is developed by inactivating rodent alpha-synuclein and introducing human alpha-synuclein transgene, then the model reliability for studying MSA is improved, but the device complexity and manufacturing difficulty increase
Solution Approach 1:
The patent creates a transgenic mouse model that copies the human alpha-synuclein gene expression pattern found in MSA patients. The human SNCA transgene is introduced under the control of the human synuclein promoter, replicating the human disease state in a rodent model. This copying approach ensures the model accurately reflects human MSA pathology while maintaining the simplicity of a mouse system.
2Loss of information
If bacterial infection is used to trigger synucleinopathy in the mouse model, then the understanding of disease etiology is improved, but the difficulty of detecting and measuring disease progression increases
Solution Approach 1:
The patent uses bacterial infection as an intermediary trigger to initiate synucleinopathy in the transgenic mouse model. Specifically, E. coli infection of the urinary bladder serves as a peripheral trigger that activates the human alpha-synuclein expression and aggregation pathway, mimicking the proposed etiology of MSA. This intermediary approach allows researchers to study disease initiation while using established bacterial infection models with well-characterized detection methods.
Data Source
Figure 1
Figure 2a~2e
Figure 2f~2h
AI summary
The invention relates to non-therapeutic methods of screening a candidate compound for use as a drug for the treatment or prevention of a demyelinating disease using transgenic rodent wherein the expression of wild type rodent alpha synuclein is inactivated and carrying a transgenic construct expressing human alpha synuclein in neurons and oligodendrocytes.